Albuterol
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
A short-acting beta-2 adrenergic agonist (SABA) that is the most widely used rescue inhaler for acute bronchospasm. The cornerstone of acute asthma and COPD symptom relief, providing rapid bronchodilation within minutes. Used for the relief and prevention of bronchospasm in asthma, exercise-induced bronchospasm, and COPD. Also used in nebulized form for acute exacerbations in emergency settings. Overuse (>2 days/week) suggests inadequate controller therapy.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
A short-acting beta-2 adrenergic agonist (SABA) that is the most widely used rescue inhaler for acute bronchospasm. NutriStack rates the supporting evidence as strong. Common adult dosing is MDI: 1-2 puffs (90-180 mcg) every 4-6 hours as needed; nebulizer: 2.5 mg every 4-8 hours; exercise prophylaxis: 2 puffs 15-30 minutes before exercise (as prescribed by your physician), though a prescriber sets the actual dose. This profile indexes 10 sources.
The bottom line
Evidence rating strong. Most-documented uses: rapid relief of acute bronchospasm (rescue inhaler), prevents exercise-induced bronchospasm, treats acute asthma exacerbations. 10 sources indexed (2013–2025), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Selectively activates beta-2 adrenergic receptors on bronchial smooth muscle cells. Receptor activation stimulates adenylyl cyclase, increasing intracellular cAMP, which activates protein kinase A (PKA). PKA phosphorylates and inactivates myosin light chain kinase (MLCK), reducing intracellular calcium and causing smooth muscle relaxation and bronchodilation. Also stabilizes mast cell membranes (reducing mediator release), increases mucociliary clearance, and decreases microvascular permeability.8
Dosing & protocol.
Delivered by inhalation for rapid local effect. Onset within 5-15 minutes, duration 4-6 hours. Proper inhaler technique is critical for drug delivery. Use a spacer with MDI for improved lung deposition. Shake MDI well before each use.10
Full safety detail.
Side effects
- Tremor (especially hands)
- Tachycardia and palpitations
- Nervousness and anxiety
- Headache
- Throat irritation and cough
- Hypokalemia (with frequent/high dosing)
- Hyperglycemia (with frequent use)
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
5- 1Salbutamol in 5q spinal muscular atrophy: a systematic review and meta-analysis of efficacy and safetyPMIDXing X, Zhao S, Jiang R et al. · European journal of pediatrics · 2025
Xing X, Zhao S, Jiang R et al.. Salbutamol in 5q spinal muscular atrophy: a systematic review and meta-analysis of efficacy and safety. European journal of pediatrics. 2025
- 2Salbutamol in Congenital Myasthenic Syndrome: A Systematic ReviewPMIDTakhman M, Shihab R, Hattab M et al. · BMC neurology · 2025
Takhman M, Shihab R, Hattab M et al.. Salbutamol in Congenital Myasthenic Syndrome: A Systematic Review. BMC neurology. 2025
- 3Safety outcomes of salbutamol: A systematic review and meta-analysisPMIDMa LH, Jia L, Bai L · The clinical respiratory journal · 2023
Ma LH, Jia L, Bai L. Safety outcomes of salbutamol: A systematic review and meta-analysis. The clinical respiratory journal. 2023
- 4Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping controlPMIDCourlet P, Buclin T, Biollaz J et al. · CPT: pharmacometrics & systems pharmacology · 2022
Courlet P, Buclin T, Biollaz J et al.. Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control. CPT: pharmacometrics & systems pharmacology. 2022
- 5Levalbuterol versus albuterol for acute asthma: a systematic review and meta-analysisPMIDJat KR, Khairwa A · Pulmonary pharmacology & therapeutics · 2013
Jat KR, Khairwa A. Levalbuterol versus albuterol for acute asthma: a systematic review and meta-analysis. Pulmonary pharmacology & therapeutics. 2013
Reference material
5- 6GINA (Global Initiative for Asthma). Global Strategy for Asthma Management and Prevention. 2023.Source linkedPMID
- 7GOLD (Global Initiative for Chronic Obstructive Lung Disease). Global Strategy for the Diagnosis, Management, and Prevention of COPD. 2023.Source linkedPMID
- 8Cates CJ et al. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev. 2013.Source linkedPMID
- 9Pierantoni L, Muratore E, Cerasi S et al.. Salbutamol safety in children under 2 years of age with acute wheezing: a meta-analysis of randomised controlled trials. Archives of disease in childhood. 2025Source linkedPMID
- 10Payares-Salamanca L, Contreras-Arrieta S, Florez-García V et al.. Metered-dose inhalers versus nebulization for the delivery of albuterol for acute exacerbations of wheezing or asthma in children: A systematic review with meta-analysis. Pediatric pulmonology. 2020Source linkedPMID
Common questions.
Quick answers about Albuterol, drawn from the data on this page.
What is Albuterol?
A short-acting beta-2 adrenergic agonist (SABA) that is the most widely used rescue inhaler for acute bronchospasm. The cornerstone of acute asthma and COPD symptom relief, providing rapid bronchodilation within minutes. Used for the relief and prevention of bronchospasm in asthma, exercise-induced bronchospasm, and COPD. Also used in nebulized form for acute exacerbations in emergency settings. Overuse (>2 days/week) suggests inadequate controller therapy.
What is Albuterol used for?
Commonly cited benefits of Albuterol include: Rapid relief of acute bronchospasm (rescue inhaler); Prevents exercise-induced bronchospasm; Treats acute asthma exacerbations; Treats acute COPD exacerbations; Nebulized for emergency department management of severe asthma. NutriStack rates the overall evidence as strong.
What is a typical dose of Albuterol?
A typical adult dose of Albuterol is MDI: 1-2 puffs (90-180 mcg) every 4-6 hours as needed; nebulizer: 2.5 mg every 4-8 hours; exercise prophylaxis: 2 puffs 15-30 minutes before exercise (as prescribed by your physician). The commonly recommended form is Metered-dose inhaler (MDI), nebulizer solution, or dry powder inhaler. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Albuterol?
Reported side effects include tremor (especially hands), tachycardia and palpitations, nervousness and anxiety, headache, throat irritation and cough, hypokalemia (with frequent/high dosing). This is educational information; check with a healthcare professional before use.
How strong is the evidence for Albuterol?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Albuterol in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.